USPSTF Backs Cervical Cancer Screening With Cytology or hrHPV
WEDNESDAY, Sept. 13, 2017 -- The U.S. Preventive Services Task Force (USPSTF) recommends cervical cancer screening with cervical cytology alone every three years or screening with high-risk human papillomavirus (hrHPV) testing alone every five years in women ages 30 to 65 years. These findings form the basis of a draft recommendation statement published online Sept. 12 by the USPSTF.
Researchers from the USPSTF reviewed the benefits and harms of screening for cervical cancer using hrHPV testing as the screening strategy with or without cervical cytology in women aged 21 years or older.
For women aged 21 to 29 years, the USPSTF recommends screening for cervical cancer with cervical cytology alone every three years. For women aged 30 to 65 years, the USPSTF recommends screening every three years with cervical cytology alone or every five years with hrHPV testing alone (A recommendation). For women aged older than 65 years who have had adequate prior screening and are not considered at high risk for cervical cancer, for those without a cervix, and for women aged younger than 21 years, the USPSTF recommends against screening for cervical cancer (D recommendation). These findings form the basis of a draft recommendation statement, which is available for public comment from Sept. 12 through Oct. 9, 2017.
"Most cases of cervical cancer occur in women who have not been regularly screened or treated," USPSTF member Carol Mangione, M.D., M.S.P.H., said in a statement.
© 2019 HealthDay. All rights reserved.
Posted: September 2017